{"id":6666,"date":"2024-11-21T14:56:09","date_gmt":"2024-11-21T13:56:09","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6666"},"modified":"2025-04-28T21:54:11","modified_gmt":"2025-04-28T19:54:11","slug":"saffron-103-a-phase-1b-study-of-the-safety-and-efficacy-of-sitravatinib-combined-with-tislelizumab-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/saffron-103-a-phase-1b-study-of-the-safety-and-efficacy-of-sitravatinib-combined-with-tislelizumab-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer\/","title":{"rendered":"SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6666","publication","type-publication","status-publish","hentry","disease_state-non-small-cell-lung-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6666"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}